What it is
Dihexa is a small compound derived from angiotensin IV, developed by researchers at Washington State University.
It was designed to act on the hepatocyte growth factor system, which is involved in synaptogenesis — the formation of new connections between neurons. It is one of several entries filed under focus and mood. Because it is a derivative rather than a plain short peptide, it resists breakdown in the body better than most of what is in this library, which was part of the design intent.
Where its reputation comes from
Almost entirely from potency figures reported in preclinical work. The numbers are striking, and they travel extremely well in marketing copy.
It is worth being precise about what such a figure means. Potency in a cell assay describes how strongly a molecule engages its target at a given concentration. It does not describe whether engaging that target helps anyone. It says nothing about dose in a person, nothing about what else the compound does, nothing about safety, and nothing about duration.
A very large potency number and a useful drug are different claims. Dihexa has the first.
What has been shown
Cell work and rodent studies. Cognitive measures in animal models.
No published human trial evidence was located. This compound has never been through a human trial that reached the literature. Semax sits at the other end of that scale: a compound in the same broad category that has been prescribed in one country for decades.
That makes the gap between what is claimed for it and what has been demonstrated about as wide as it gets in this library.
The question nobody has answered
There is an assumption buried in the enthusiasm: that promoting new neural connections is straightforwardly good.
The brain spends considerable effort pruning connections as well as forming them. Which connections exist, and which are removed, is not incidental to how a brain works — it is much of how it works.
More generally, "promotes growth-factor signalling in tissue" is also the description of a category of problem nobody wants. Whether that concern applies here is unknown, and unknown is the accurate word: with no human data, there is no observation period, no adverse-event record, and nothing to look at.
Where it stands
Approved as a medicine: nowhere.
Human evidence: none located.
Sold as: a research chemical.
Last checked
2026-09-07.